Sumatriptan is a selectiveagonist of 5HT1 (1B/1D) receptors,which has proved to be effectiveand safe for the acute treatment ofmigraine attacks. Nevertheless, itsuse by migraine sufferers is stilllimited and some patients consideradverse reactions related to sumatriptan,especially chest symptoms,unacceptable even if not serious.Moreover, in clinical trials, almostone third and one sixth of patients,respectively, fail to experienceheadache relief either after oral orafter subcutaneous sumatriptanadministration. Our aim was to verifywhether differencies in sumatriptanpharmacokinetics couldexplain non-response and/oradverse drug reactions. Sumatriptanlevels were determined by HPLCwith electrochemical detection.Pharmacokinetic parameters werecalculated using a computer program(PK Solutions 2.0; non compartmentalPharmacokinetics DataAnalysis). After oral administration,sumatriptan is rapidly absorbed andsometimes displays multiple peaksof plasma concentration. This “multiplepeaking” gives rise to considerableinter-subject variability inthe time of reaching maximumplasma concentration.Pharmacokinetic parameters ofsumatriptan, both after oral andsubcutaneous administration, weresimilar in the three patient groups.Blood pressure and heart rate didnot show any significant differencesbetween groups. Pharmacokineticparameters and bioavailability ofsumatriptan did not seem to be correlatedeither to the lack of efficacyor the appearance of side effects.These results could depend on thelimited number of patients studied.

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients / Sternieri, Emilio; Pinetti, Diego; C. P. R., Coccia; S., Leone; Bertolini, Alfio; Ferrari, Anna. - In: THE JOURNAL OF HEADACHE AND PAIN. - ISSN 1129-2369. - STAMPA. - 6(2005), pp. 319-321. [10.1007/s10194-005-0220-z]

Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients

STERNIERI, Emilio;PINETTI, Diego;BERTOLINI, Alfio;FERRARI, Anna
2005

Abstract

Sumatriptan is a selectiveagonist of 5HT1 (1B/1D) receptors,which has proved to be effectiveand safe for the acute treatment ofmigraine attacks. Nevertheless, itsuse by migraine sufferers is stilllimited and some patients consideradverse reactions related to sumatriptan,especially chest symptoms,unacceptable even if not serious.Moreover, in clinical trials, almostone third and one sixth of patients,respectively, fail to experienceheadache relief either after oral orafter subcutaneous sumatriptanadministration. Our aim was to verifywhether differencies in sumatriptanpharmacokinetics couldexplain non-response and/oradverse drug reactions. Sumatriptanlevels were determined by HPLCwith electrochemical detection.Pharmacokinetic parameters werecalculated using a computer program(PK Solutions 2.0; non compartmentalPharmacokinetics DataAnalysis). After oral administration,sumatriptan is rapidly absorbed andsometimes displays multiple peaksof plasma concentration. This “multiplepeaking” gives rise to considerableinter-subject variability inthe time of reaching maximumplasma concentration.Pharmacokinetic parameters ofsumatriptan, both after oral andsubcutaneous administration, weresimilar in the three patient groups.Blood pressure and heart rate didnot show any significant differencesbetween groups. Pharmacokineticparameters and bioavailability ofsumatriptan did not seem to be correlatedeither to the lack of efficacyor the appearance of side effects.These results could depend on thelimited number of patients studied.
6
319
321
Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients / Sternieri, Emilio; Pinetti, Diego; C. P. R., Coccia; S., Leone; Bertolini, Alfio; Ferrari, Anna. - In: THE JOURNAL OF HEADACHE AND PAIN. - ISSN 1129-2369. - STAMPA. - 6(2005), pp. 319-321. [10.1007/s10194-005-0220-z]
Sternieri, Emilio; Pinetti, Diego; C. P. R., Coccia; S., Leone; Bertolini, Alfio; Ferrari, Anna
File in questo prodotto:
File Dimensione Formato  
Pharmacokinetics of sumatriptan in nonrespondent.pdf

accesso aperto

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 35.45 kB
Formato Adobe PDF
35.45 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/595049
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 14
  • ???jsp.display-item.citation.isi??? ND
social impact